Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs - PubMed (original) (raw)
Comparative Study
. 2004 Nov;18(14):1737-9.
doi: 10.1096/fj.04-2192fje. Epub 2004 Sep 2.
Affiliations
- PMID: 15345695
- DOI: 10.1096/fj.04-2192fje
Comparative Study
Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs
Paolo Madeddu et al. FASEB J. 2004 Nov.
Abstract
Hematopoietic progenitor cell transplantation can contribute to revascularization of ischemic tissues. Yet, the optimal cell population to be transplanted has yet to be determined. We have compared the therapeutic potential of two subsets of human cord blood CD34+ progenitors, either expressing the VEGF-A receptor 2 (KDR) or not. In serum-free starvation culture, CD34+KDR+ cells reportedly showed greater resistance to apoptosis and ability to release VEGF-A, as compared with CD34+KDR- cells. When injected into the hind muscles in immunodeficient SCIDbg mice subjected to unilateral ischemia, a low number (10(3)) of CD34+KDR+ cells improved limb salvage and hemodynamic recovery better than a larger dosage (10(4)) of CD34+KDR- cells. The neovascularization induced by KDR+ cells was significantly superior to that promoted by KDR- cells. Similarly, endothelial cell apoptosis and interstitial fibrosis were significantly attenuated by KDR+ cells, which differentiated into mature human endothelial cells and also apparently skeletal muscle cells. This study demonstrates that a low number of CD34+KDR+ cells favors reparative neovascularization and possibly myogenesis in limb ischemia, suggesting the potential use of this cell population in regenerative medicine.
Similar articles
- Umbilical cord blood-derived aldehyde dehydrogenase-expressing progenitor cells promote recovery from acute ischemic injury.
Putman DM, Liu KY, Broughton HC, Bell GI, Hess DA. Putman DM, et al. Stem Cells. 2012 Oct;30(10):2248-60. doi: 10.1002/stem.1206. Stem Cells. 2012. PMID: 22899443 - [Transplantation of cord blood endothelial progenitor cells ameliorates limb ischemia].
Yang C, Zhang ZH, Lu SH, Yang RC, Qian GQ, Han ZC. Yang C, et al. Zhonghua Yi Xue Za Zhi. 2003 Aug 25;83(16):1437-41. Zhonghua Yi Xue Za Zhi. 2003. PMID: 14521750 Chinese. - Heart infarct in NOD-SCID mice: therapeutic vasculogenesis by transplantation of human CD34+ cells and low dose CD34+KDR+ cells.
Botta R, Gao E, Stassi G, Bonci D, Pelosi E, Zwas D, Patti M, Colonna L, Baiocchi M, Coppola S, Ma X, Condorelli G, Peschle C. Botta R, et al. FASEB J. 2004 Sep;18(12):1392-4. doi: 10.1096/fj.03-0879fje. Epub 2004 Jul 1. FASEB J. 2004. PMID: 15231728 - CD34-positive stem cells: in the treatment of heart and vascular disease in human beings.
Mackie AR, Losordo DW. Mackie AR, et al. Tex Heart Inst J. 2011;38(5):474-85. Tex Heart Inst J. 2011. PMID: 22163120 Free PMC article. Review. - Regeneration of the vascular compartment.
Becher MU, Nickenig G, Werner N. Becher MU, et al. Herz. 2010 Aug;35(5):342-51. doi: 10.1007/s00059-010-3360-0. Herz. 2010. PMID: 20842474 Review.
Cited by
- Exosomes derived from human CD34+ stem cells transfected with miR-26a prevent glucocorticoid-induced osteonecrosis of the femoral head by promoting angiogenesis and osteogenesis.
Zuo R, Kong L, Wang M, Wang W, Xu J, Chai Y, Guan J, Kang Q. Zuo R, et al. Stem Cell Res Ther. 2019 Nov 15;10(1):321. doi: 10.1186/s13287-019-1426-3. Stem Cell Res Ther. 2019. PMID: 31730486 Free PMC article. - Stem/Progenitor Cells and Their Therapeutic Application in Cardiovascular Disease.
Hou Y, Li C. Hou Y, et al. Front Cell Dev Biol. 2018 Oct 18;6:139. doi: 10.3389/fcell.2018.00139. eCollection 2018. Front Cell Dev Biol. 2018. PMID: 30406100 Free PMC article. Review. - Autologous Stem Cell Therapy for Chronic Lower Extremity Wounds: A Meta-Analysis of Randomized Controlled Trials.
Chiang KJ, Chiu LC, Kang YN, Chen C. Chiang KJ, et al. Cells. 2021 Nov 25;10(12):3307. doi: 10.3390/cells10123307. Cells. 2021. PMID: 34943815 Free PMC article. - A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia.
Losordo DW, Kibbe MR, Mendelsohn F, Marston W, Driver VR, Sharafuddin M, Teodorescu V, Wiechmann BN, Thompson C, Kraiss L, Carman T, Dohad S, Huang P, Junge CE, Story K, Weistroffer T, Thorne TM, Millay M, Runyon JP, Schainfeld R; Autologous CD34+ Cell Therapy for Critical Limb Ischemia Investigators. Losordo DW, et al. Circ Cardiovasc Interv. 2012 Dec;5(6):821-30. doi: 10.1161/CIRCINTERVENTIONS.112.968321. Epub 2012 Nov 27. Circ Cardiovasc Interv. 2012. PMID: 23192920 Free PMC article. Clinical Trial. - Decellularized Aortic Scaffold Alleviates H2O2-Induced Inflammation and Apoptosis in CD34+ Progenitor Cells While Driving Neovasculogenesis.
Gao L, Feng A, Li C, Schmull S, Sun H. Gao L, et al. Biomed Res Int. 2020 Feb 10;2020:6782072. doi: 10.1155/2020/6782072. eCollection 2020. Biomed Res Int. 2020. PMID: 32104703 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources